The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
6 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,578,900 in first-year total cost, median $267,748.
Most frequent study sections
- Special Emphasis Panel[ZRG1 EMNR-W (10)]4
- Special Emphasis Panel[ZRG1 CVRS-C (10)]1
- Special Emphasis Panel[ZRG1 DKUS-L (11)]1
Most frequent institutions
- GRUTHAN BIOSCIENCE LLC1
- HGG RESEARCH, LLC1
- MAKSCIENTIFIC, LLC1
- RIDGELINE THERAPEUTICS, LLC1
- SERPLUS TECHNOLOGY, LLC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Novel therapeutic for treatment of type 1 diabetes1R41DK122917-01A1 | MALONEY, DAVID JOSEPHMIRMIRA, RAGHAVENDRA G | VERALOX THERAPEUTICS, INC, MD | $300,000 | ZRG1 |
| 2020 | Analysis of new compounds to treat familial hypercholesterolemia1R41HL156602-01 | DUNCAN, STEPHEN A | GRUTHAN BIOSCIENCE LLC, SC | $296,495 | ZRG1 |
| 2019 | Prevention of type 1 diabetes using early glycation products1R41DK121553-01 | CHEN, YINGJIAGUO, TAI L | HGG RESEARCH, LLC, GA | $239,000 | ZRG1 |
| 2019 | Lead Optimization of Peripheral CB1 Neutral Antagonists for Renal Diseases1R41DK115303-01A1 | MAKRIYANNIS, ALEXANDROS | MAKSCIENTIFIC, LLC, MA | $224,999 | ZRG1 |
| 2018 | Dose-ranging safety and efficacy studies to advance novel mechanism-of-action small molecule leads to treat obesity-linked type 2 diabetes1R41DK119052-01 | WATOWICH, STANLEY | RIDGELINE THERAPEUTICS, LLC, TX | $299,972 | ZRG1 |
| 2018 | Regulation of Autoimmune Type 1 Diabetes by Serpins B1 and A1 (Alpha 1-Antitrypsin)1R41DK115326-01A1 | KULKARNI, ROHIT N.PEMBERTON, PHILIP | SERPLUS TECHNOLOGY, LLC, CA | $218,434 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.